This Biotech Stock Is Up 355%. One Fund Added a $169 Million Position Last Quarter This biotechnology firm develops clinical-stage therapies for autoimmune and neuroinflammatory diseases using proprietary TYK2 inhibitors.
Dyne Therapeutics Is Up 40%, but One Biotech Fund Just Disclosed Selling $14 Million Worth of Shares This clinical-stage biotech develops therapies for rare muscle diseases, leveraging its FORCE platform to target significant unmet needs.
What This Fund’s $14 Million Ocular Therapeutix Exit Could Signal for Investors Ocular Therapeutix delivers ophthalmic therapies with hydrogel technology and a pipeline targeting retinal and glaucoma conditions.
What to Know About This Fund’s New $22 Million Xenon Pharmaceuticals Buy Ahead of an FDA Filing Xenon Pharmaceuticals develops therapies for neurological disorders, with a pipeline targeting epilepsy and related conditions.
Dianthus Therapeutics Is Up 320% in a Year. One Major Investor Just Reduced Its Stake but Still Seems Bullish Specializing in monoclonal antibody therapies, this clinical-stage biotech targets severe autoimmune and inflammatory diseases.
Alumis Stock Has Soared 400%. Cormorant Bought Another $8 Million Last Quarter Alumis develops clinical-stage therapies targeting autoimmune and neuroinflammatory diseases through proprietary TYK2 inhibitors.
Alumis Stock Is Up Over 300%. One Major Healthcare Investor Is Cutting Back Alumis Inc. develops clinical-stage therapies targeting autoimmune and neuroinflammatory diseases using allosteric TYK2 inhibitors.
Why One Fund’s $4 Million Alumis Buy Looks Like a Bet on a Breakthrough Autoimmune Drug Alumis develops clinical-stage therapies targeting autoimmune and neuroinflammatory diseases with a focus on TYK2 inhibition technology.
Alumis Stock Has Rallied 250% This Past Year. One Fund Sold Its $5 Million Stake Last Quarter. This clinical-stage biotech develops therapies targeting autoimmune and neuroinflammatory diseases with a focus on TYK2 inhibition.
An Almus (ALMS) Insider Bought 588,000 Shares for $10.0 Million Biotech innovator Alumis, focused on autoimmune therapies, reported a significant insider buy amid a year of robust stock gains.
Stock Market Today, Jan. 6: Alumis Shares Surge on Positive Phase 3 Psoriasis Data for Envudeucitinib Investors today are cheering envudeucitinib's Phase 3 edge in oral TYK2 psoriasis as well as Alumis' plans to raise fresh capital.
The Great Rotation: Small-Caps Lead 2026 Market Charge as Tech Giants Stumble The first week of 2026 has delivered a definitive verdict on the next phase of the bull market: the era of mega-cap dominance is yielding to the rise of the small-cap. In a dramatic "Great Rotation," investors are pulling capital from the expensive, AI-saturated titans of the Nasdaq and pouring
Why Is ALMS Stock Rising Today? Alumis announced positive results from both of its Phase 3 clinical trials of envudeucitinib.
